Table 1.
Clinical characteristics and demographics of patients with atrial fibrillationa
| Number of patients | 81 |
| Number of measurements | 276 |
| Sex (male/female) | 61/20 |
| Age (years) | 68.1 (40.5–84.9) |
| Body weight (kg) | 65.0 (41.0–92.2) |
| Dosage of apixaban (mg day −1 ) | 10 (5–20) |
| Plasma concentration of apixaban (ng ml −1 ) | 157.9 (15.6–673.6) |
| Serum creatinine (mg dl −1 ) | 0.88 (0.41–1.34) |
| Creatinine clearance (ml min −1 ) | 69.8 (30.6–145.5) |
| Aspartate amino transferase (IU l −1 ) | 23 (13–97) |
| Alanine amino transferase (IU l −1 ) | 19 (5–115) |
| Number of patients treated with CYP3A4 and/or P‐glycoprotein inhibitors | |
| Amiodarone | 17 |
| Verapamil | 6 |
| Number of patients with co‐morbidities | |
| Hypertension | 36 |
| Diabetes mellitus | 34 |
| Heart failure | 20 |
| Dyslipidemia | 18 |
a
Data are presented as the number or median with the range in parentheses.